Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | TYR | P14679 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-Methyl Cinnamate SCHEMBL112062 | 1.00 | CA12 (0.69) | CA12CA1CA2TYRCA7 | |
| E-Methyl Cinnamate SCHEMBL27554805 | 1.00 | CA12 (0.69) | CA12CA1CA2TYRCA7 | |
| E-Methyl Cinnamate SCHEMBL27554806 | 1.00 | CA12 (0.69) | CA12CA1CA2TYRCA7 | |
| E-Methyl Cinnamate SCHEMBL1862419 | 1.00 | CA12 (0.69) | CA12CA1CA2TYRCA7 | |
| E-Methyl Cinnamate SCHEMBL101530 | 1.00 | CA12 (0.69) | CA12CA1CA2TYRCA7 | |
| E-Methyl Cinnamate SCHEMBL901224 | 1.00 | CA12 (0.69) | CA12CA1CA2TYRCA7 | |
| E-Methyl Cinnamate SCHEMBL28606972 | 0.98 | CA12 (0.67) | CA12CA1CA2TYRCA7 | |
| E-Methyl Cinnamate SCHEMBL28577208 | 0.98 | CA12 (0.67) | CA12CA1CA2TYRCA7 | |
| E-Methyl Cinnamate SCHEMBL6327040 | 0.98 | CA12 (0.67) | CA12CA1CA2TYRCA7 | |
| E-Methyl Cinnamate SCHEMBL11725144 | 0.98 | CA12 (0.67) | CA12CA1CA2TYRCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101598-B1 | TOBACCO PRODUCT, PREPARATION AND USES THEREOF | BRITISH AMERICAN TOBACCO CO (GB) | 2011-09-28 | — | — | EP | claimed |
| US-20100126520-A1 | Tobacco Product, Preparation and Uses Thereof | BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) | 2010-05-27 | — | — | US | claimed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| US-12324451-B2 | Production of ethanol-free vanilla extracts | SYMRISE AG (DE) | 2025-06-10 | — | — | US | disclosed |
| US-12303488-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-05-20 | — | — | US | disclosed |
| CN-119662342-A | Method for improving content of methyl cinnamate in basil essential oil | 韶关学院 | 2025-03-21 | — | — | CN | disclosed |
| US-12240810-B2 | Chiral-substituted poly-N-vinylpyrrolidinones and complexes with bimetallic nanoclusters and uses thereof in asymmetric oxidation reactions | KANSAS STATE UNIVERSITY RESEARCH (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4417252-A2 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | Yuzu LV LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2006072393-A2 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI-AVENTIS (DE) | 2006-07-13 | — | — | WO | disclosed |
| US-5663393-A | CYCLIZATION; DECYCLIZATION; HYDROLYSIS; HYDROGENATION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5637739-A | ORGANOMETALLIC CATALYSTS FOR ENANTIOSELECTIVELY EPOXIDIZING PROCHIRAL OLEFINS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0643626-A4 | CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL. | RES CORP TECHNOLOGIES INC (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0643626-A1 | CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-03-22 | — | — | EP | disclosed |
| WO-1993003838-A1 | CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| CN-1017892-B | PURE ENANTIOMERS OF 4,5-DISUBSTITUTED R-BUTYROLACTAMS, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1992-08-19 | — | — | CN | disclosed |
| CN-87103770-A | 4,5 two replace the pure enantiomorph of butyrolactam, their preparation method and application | — | 1988-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A2, SLC6A3 | CA12 4401/4885CA1 2944/4885CA2 3670/4885 |
| US-12240810-B2 | Chiral-substituted poly-N-vinylpyrrolidinones and complexes with bimetallic nanoclusters and uses thereof in asymmetric oxidation reactions | DHPS, PCBP1, PNKP | CA12 1551/4885CA1 1722/4885CA2 1771/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | CA12 2193/4885CA1 4429/4885CA2 3943/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | CA12 1134/4885CA1 1528/4885CA2 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.